Skip to main content
Premium Trial:

Request an Annual Quote

CyVek Nets $2M in Private Placement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Life science technologies start-up CyVek has netted almost $2 million through a private equity offering, according to a filing with the US Securities and Exchange Commission.

The firm is based in Wallingford, Conn.

According to a profile for CyVek CEO and President Per Hellsund on the networking website LinkedIn, the company's technology will be used in clinical diagnostic settings, and it is based on a novel microfluidic test cartridge that may be coupled with a multiplex system.

According to the SEC filing, the $1.95 million in funding came from five investors. The company did not state in the filing how the funding will be used.

Hellsund formerly was president of inc.jet Inc. and he was VP of operations at Gunther International.

In addition, listed as an executive officer and director of the firm is Kevin Didden, the president and CEO of process monitoring technologies firm CiDRA and former chairman of CyVera, the digital microbead technology developer that was acquired in 2004 by Illumina. That technology has since been launched by Illumina under the BeadXpress name.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.